Shanxi Taisheng Pharmaceutical Co., Ltd.

Primary objective: To evaluate the bioequivalence of cefixime granules (specification: 50 mg; manufacturer: Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd.; test preparation) and cefixime fine granules (specification: 50 mg; manufacturer: Choseido Pharmaceutical Co., Ltd.; trade name: Cefspan®; reference preparation) orally administered to healthy subjects on an empty stomach or after meals, and to compare the absorption rate and extent of the test preparation and the reference preparation. Secondary objective: To observe the safety of the test preparation cefixime granules and the reference preparation cefixime fine granules (Cefspan®) in healthy subjects.

A bioequivalence study was conducted using cefixime capsules produced by Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd. as the test preparation and cefixime capsules (trade name: Cefspan®) produced by Choseido Pharmaceutical Co., Ltd. as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two cefixime capsules in healthy volunteers under fasting and postprandial conditions were investigated to evaluate whether the test preparation and the reference preparation are bioequivalent preparations and their safety.

Preliminary evaluation of the safety and efficacy of astragaloside sodium chloride injection in the treatment of chronic stable angina pectoris